Mavacamten: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1127, doi. 10.1007/s40265-022-01739-7
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2022 AND VI 82 AND IP 10
Results: 8
1
2
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1027, doi. 10.1007/s40265-022-01747-7
- By:
- Publication type:
- Article
3
Nemolizumab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1143, doi. 10.1007/s40265-022-01741-z
- By:
- Publication type:
- Article
4
Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1055, doi. 10.1007/s40265-022-01743-x
- By:
- Publication type:
- Article
5
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1095, doi. 10.1007/s40265-022-01745-9
- By:
- Publication type:
- Article
6
Serplulimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1137, doi. 10.1007/s40265-022-01740-0
- By:
- Publication type:
- Article
7
Estetrol/Drospirenone: A Review in Oral Contraception.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1117, doi. 10.1007/s40265-022-01738-8
- By:
- Publication type:
- Article
8
Improving Treatment Options for Primary Hyperoxaluria.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1077, doi. 10.1007/s40265-022-01735-x
- By:
- Publication type:
- Article